NEW YORK (GenomeWeb) – Alion Pharmaceuticals and the Medical Prognosis Institute today announced a partnership to develop a companion diagnostic for Alion's ion channel inhibitors used in the treatment of certain cancers.

MPI will use its Drug Response Predictor platform to identify a biomarker that Alion can use to help find cancer patients likely to respond to its lead ion channel inhibitor. Alion would use the companion diagnostic to enroll patients for a planned Phase I clinical trial.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.